ABCL
Abcellera Biologics Inc
NASDAQ: ABCL · HEALTHCARE · BIOTECHNOLOGY
$13.64
+6.31% today
Updated 2026-10-28
Market cap
$3.82B
P/E ratio
—
P/S ratio
57.79x
EPS (TTM)
$-0.54
Dividend yield
—
52W range
$3 – $15
Volume
5.0M
Abcellera Biologics Inc (ABCL) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$13.64
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$6.92
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.5B | $0.0B | $0.0B | $0.1B | $0.1B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: -20.27% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -248.80%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.